J Obes Metab Syndr 2019; 28(3): 158-166
Published online September 30, 2019 https://doi.org/10.7570/jomes.2019.28.3.158
Copyright © Korean Society for the Study of Obesity.
Department of Internal Medicine, Seoul National University College of Medicine, Seoul; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea
Tae Jung Oh
Department of Internal Medicine, Seoul National University College of Medicine and Department of Internal Medicine, Seoul National University Bundang Hospital, 82 Gumi-ro 173beon-gil, Bundang-gu, Seongnam 13620, Korea
Tel: +82-31-787-7078 Fax: +82-31-787-4050 E-mail: firstname.lastname@example.org
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Diabetes is prevalent in obese population, and obesity management is the first step in preventing diabetes. Traditionally, lifestyle modification including reduced-calorie diet, physical activity, and behavior intervention is the core of obesity management. However, pharmacotherapy is frequently required in addition to the lifestyle modification for effective reduction of body weight. There are five classes of anti-obesity medications approved by the U.S. Food and Drug Administration for chronic treatment used in obesity management. As the goal of obesity management is to prevent obesity-related comorbidities, clinical trials were conducted to evaluate the effect of anti-obesity medications on cardiovascular risk factors including hyperglycemia. Orlistat and liraglutide have been tested for their effect on diabetes prevention as a primary outcome. Cardiovascular safety studies were conducted for lorcaserin and liraglutide (as an anti-diabetic medication). In addition, there are many indirect evidences of the role of anti-obesity medications on diabetes prevention and its microvascular and macrovascular complications. This review focused on current evidences of anti-obesity medications related with diabetes, which is a major complication of obesity.
Keywords: Obesity, Diabetes mellitus, Drug therapy, Cardiovascular disease, Diabetes complications
The prevalence of obesity has doubled since 1980 and this trend has continued over time.1 This is a serious global health problem and we need appropriate prevention strategies for obesity itself and obesity related comorbidities. Diabetes is the most hazardous obesity related comorbidity and it can be prevented by reducing body weight.2,3 Furthermore, for the individuals who already suffer from diabetes, a larger body weight reduction brought a better glucose control and health benefit on one year4 and even longer term.5 Reducing hyperglycemia is one of the most important prevention strategies for diabetes complications.6,7 Moreover, obesity management is important not only for the prevention of diabetes but also for the delay of diabetes related complications.
Life style modification including healthy meal plan, increase of physical activity, and behavior intervention is an essential part of obesity management.8 However, majority of patients need pharmacotherapy to control their body weight effectively. Currently, there are five classes of pharmacotherapy for obesity, which have been approved by the U.S. Food and Drug Administration (FDA) for chronic treatment. These are orlistat, lorcaserin, phentermine/topiramate extended-release (ER), naltrexone sustained release (SR)/bupropion SR, and liraglutide 3.0 mg. In this review, I focused on the evidence and mechanistic explanation of each drug in preventing diabetes and its complications.
The Finnish Diabetes Prevention Study (DPS) and Diabetes Prevention Program (DPP) demonstrated that intensive lifestyle modification reduced the incidence of diabetes by 58% compared to placebo during around 3 years.9,10 The study participants of DPS were given detailed advice to reduce their body weight by 5% or more including dietary advice and individual guidance for physical activity.10 In DPP, subjects participated a 16-session one to one curriculum of diet, exercise, and behavioral modification to achieve the goal of body weight reduction (at least 7% of baseline body weight).9 They were encouraged to follow healthy low calorie, low-fat diet and at least 150 minutes of moderate intensity exercise per week. At the end of study, the body weight loss from the baseline was 4.2 kg in DPS and 5.6 kg in DPP. Therefore, life style modification is generally recommended to prevent diabetes. However, the success of life style modification is hardly achieved without a supervised program.11 Therefore, pharmacotherapy is necessary in many situations. Some of the anti-obesity medications were evaluated for their role in prevention of diabetes as a primary or secondary outcomes (Table 1).
Orlistat was approved in 1999 by the FDA as an anti-obesity medication. Orlistat is a lipase inhibitor, which prevents the absorption of dietary fat. Moreover, it is the only peripheral acting anti-obesity medication.12 According to two phase III studies performed in European countries13 and the USA,14 it has been proved that orlistat promotes a significant weight loss and improves hyperglycemia in obese subjects. A pooled analysis15 including these two studies showed that subjects with impaired glucose tolerance (IGT) less progressed to diabetes in orlistat group than the placebo group (3.0% vs. 7.6%,
Phentermine/topiramate ER is a single-pill combination of phentermine, sympathomimetic amine and topiramate, an antiepileptic drug. This drug was approved for anti-obesity medication in 2012. There were two large scale randomized double-blind, placebo-controlled studies to prove the efficacy of body weight reduction of phentermine/topiramate ER in overweight or obese subjects.20,21 However, there was no study to assess the prevention of diabetes as a primary outcome. The CONQUER study enrolled 84% of subjects without type 2 diabetes at baseline.20 In this population, development of diabetes was less in phentermine 15 mg/topiramate ER 92 mg (1.7%) group than placebo (3.6%; HR, 0.47; 95% CI, 0.25–0.88) during the 56 weeks. A total of 78.1% of subjects in CONQUER study continued to take blinded medication over 108 weeks to evaluate the long-term efficacy and safety of phentermine/topiramate ER and the name of this extended study is SEQUEL.22 In the SEQUEL study, the least square mean percentage changes of body weight from baseline were greater in high dose Phentermine/topiramate ER than placebo (−10.5% vs. −1.8%,
Lorcaserin is a 5-hyroxytryptamine receptor 2C agonist. This drug stimulates proopiomelanocortin (POMC) neurons in the hypothalamus and decreases appetite.25 This drug was approved as an anti-obesity medication in 2012. Two phase III studies26,27 including overweight and obese subjects without diabetes and one phase III study28 including those with diabetes were conducted and chronic treatment (1-year and 2-year) with lorcaserin reduced more body weight compared to placebo (5%–6% vs. 1%–2%). After these studies, CAMELLIA-TIMI 61 study was conducted independently to assess the cardiovascular safety and efficacy of lorcaserin.29 Among the study population, the prespecified primary metabolic efficacy, which is evaluated as the time to incident type 2 diabetes, was analyzed in 3,991 subjects with prediabetes at baseline.30 During a median follow-up of 3.3 years, lorcaserin reduced the risk of incidence of diabetes by 19% (HR, 0.81; 95% CI, 0.66–0.99). Furthermore, remission rate of hyperglycemia was higher in lorcaserin treatment than placebo in subjects with type 2 diabetes at baseline (HR, 1.21; 95% CI, 1.07–1.36).30 Interestingly, glycosylated hemoglobin (HbA1c) reduction occurred earlier than significant weight loss. From a preclinical study, lorcaserin suppressed hepatic glucose production via melanocortin 4 receptor signaling, which phenomenon was independent to its anorectic effect.31 Therefore, lorcaserin might have direct mechanism to reduce hyperglycemia in improving insulin sensitivity.
Naltrexone blocks the opioid-mediated POMC auto-inhibition and bupropion stimulates the hypothalamic POMC neuron. Combination of these two drugs showed synergistic effects in body weight reduction,32 and was approved as an anti-obesity medication in 2014. There were four Contrave Obesity Research (COR) studies. The COR-I,33 COR-II,34 and COR-behavior modification35 included subjects without diabetes. Among these studies, only COR-I study showed a significant decrease of fasting plasma glucose in naltrexone SR 32 mg/bupropion SR 16 mg combination treatment, but all three of the studies did not evaluate the incidence of diabetes. According to COR-Diabetes study36 including subjects with type 2 diabetes under lifestyle modification and/or oral antidiabetic medications, HbA1c levels decreased more in naltrexone SR/bupropion SR combination treatment than in placebo after 1-year (−0.6% vs. −0.1%,
Liraglutide is a GLP-1 receptor agonist and it has been first approved as an anti-diabetic medication.38 Higher dose of liraglutide (3.0 mg per day) showed greater body weight loss in a phase 2 study and the magnitude of body weight reduction was greater than orlistat.39 Following the SCALE study, a large scaled randomized double-blind, placebo-controlled study, confirmed that 3.0 mg of liraglutide effectively reduced body weight compared to the placebo (a difference of −5.6 kg; 95% CI, −6.0 to −5.1 kg;
Not only intensive glycemic control45 but also effective management of high blood pressure and dyslipidemia46 can reduce the risk of chronic diabetic complications. Therefore, anti-obesity medications have a potential role in delaying the diabetes related complications (Fig. 1).
Cardiovascular risk factors were assessed after a 1-year treatment of orlistat in subjects with diabetes.50 Total and low-density lipoprotein cholesterol, and systolic blood pressure were significantly reduced in orlistat group than the placebo group.47 In this study, 24-hour urine albumin excretion was also significantly decreased after orlistat treatment (Table 2). Therefore, orlistat induced weight reduction effectively and also controlled cardiovascular risk factors. However, there was no large scale randomized controlled trial to evaluate the major adverse cardiovascular events (MACE).
A retrospective study comparing MACE among phentermine/topiramate ER fixed dose combination, each component use, and unexposed to each drug demonstrated that phentermine/topiramate ER did not increase MACE.24 However, there was no study to demonstrate the effect of drug on diabetic microvascular and macrovascular complications.
In CAMELLIA-TIMI 61 study microvascular composite outcome (Table 2) including persistent microalbuminuria, diabetic retinopathy, and diabetic neuropathy reduced in lorcaserin than placebo (HR, 0.79; 95% CI, 0.69–0.92).30 Among them, renal composite outcome was also solely reduced in lorcaserin group than the placebo group (HR, 0.87; 95% CI, 0.79–0.96).48 This renal protective effect was globally observed across subgroups according to cardiovascular and renal risk. In summary, lorcaserin treatment was associated with reducing diabetic microvascular complications and did not increase MACE.
From June, 2012, cardiovascular safety study was started to determine whether naltrexone SR/bupropion SR combination treatment increases major cardiovascular adverse cardiovascular events.51 According to the 50% interim analysis, HR of MACE associated with treatment of naltrexone SR/bupropion SR was 0.88 (95% CI, 0.57–1.34). However, due to early termination of the study, we have no conclusive result about cardiovascular safety of naltrexone SR/bupropion SR. Therefore, there is very limited data of naltrexone SR/bupropion SR combination treatment for the effect on cardiovascular safety.
Liraglutide was firstly developed as anti-diabetic medication, and its cardiovascular safety data has been published.52 Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial demonstrated the cardiovascular safety and superiority of liraglutide 1.8 mg compared to placebo (HR, 0.87; 95% CI, 0.78–0.97). However, dosage of anti-obesity medication of liraglutide is much higher than anti-diabetic medication, which is 3.0 mg. Therefore, we cannot guarantee the cardiovascular safety or benefit of liraglutide 3.0 mg adopting the LEADER trial. A post hoc analysis of SCALE study showed no association between the chronic treatment with liraglutide 3.0 mg and the adverse cardiovascular events (HR, 0.42; 95% CI, 0.17–1.08).53 This analysis showed a broad range of CI because SCALE study enrolled subjects with relatively low cardiovascular risk compared to subjects enrolled in LEADER study. According to the available data, liraglutide as an anti-obesity medication at least did not increase cardiovascular events in long term use. Furthermore, prespecified secondary renal outcomes in LEADER trial were less detected in liraglutide than placebo (HR, 0.78; 95% CI, 0.67–0.92),49 in which the results were mainly derived by reducing albuminuria (Table 2). Likewise, the higher dose regimen of liraglutide has not been studied, whether it reduces diabetic complications as prespecified outcomes.
Since obesity is the most important risk factor for type 2 diabetes, many anti-obesity medications have been tested for their role in diabetes prevention. In addition, the effect of anti-obesity medications on diabetes related complications have been demonstrated. Many of them showed neutral effect on cardiovascular events. However, further large scale long term studies should be performed to prove their roles in cardiovascular disease and microvascular complications as well.
The author declares no conflict of interest.
Anti-obesity medications and its role in diabetes prevention
|Drug||Study name||Time to diabetes||Subject||Baseline BMI of treatment group (kg/m2)||Body weight change||Follow-up duration||HR (95% CI)|
|Orlistat||XENDOS||Primary outcome||3,305 Subjects with normal (79%) and prediabetes (21%)||37.3||−5.8 kg||4 yr||0.63 (0.46–0.86)|
|Phentermine/topiramate ER||CONQUER||Secondary outcome of subgroup||2,092 Subjects with normal and prediabetes||36.6||−10.2 kg*||56 wk||0.47 (0.25–0.88)|
|Lorcaserin||CAMELLIA-TIMI 61||Secondary outcome||3,991 Subjects with prediabetes||34.0||−2.8 kg (compared to placebo)||3.3 yr||0.81 (0.66–0.99)|
|Liraglutide||SCALE||Primary outcome||2,254 Subjects with prediabetes||38.8||−6.1%||160 wk||0.21 (0.13–0.34)|
*This data was driven in high-dose treatment subjects including diabetes.
BMI, body mass index; HR, hazard ratio; CI, confidence interval; XENDOS, Xenical in the Prevention of Diabetes in Obese Subjects; ER, extended-release.
Anti-obesity medications and its role in diabetes microvascular complications
|Author (year)||Drug||Outcome measurement||Result|
|Tong et al. (2002)47||Orlistat||The % change of 24-hour urine albumin excretion from baseline||−3.1% In subjects with diabetes and −6.7% in subjects without diabetes|
|Scirica et al. (2019)48||Lorcaserin||Composite of new or worsening persistent micro- or macroalbuminuria, new or worsening CKD, doubling of serum creatinine, ESRD, renal transplant, or renal death||HR, 0.87 (95% CI, 0.79–0.96;
|Mann et al. (2017)49||Liraglutide||Composite of new persistent macroalbuminuria, persistent doubling of serum creatinine, ESRD, or renal death||HR, 0.78 (95% CI, 0.67–0.92;
CKD, chronic kidney disease; ESRD, end-stage renal disease; HR, hazard ratio; CI, confidence interval.